Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth

[1]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[2]  S. Giordano,et al.  The Dual Roles of NRF2 in Cancer. , 2016, Trends in molecular medicine.

[3]  Lin Zhu,et al.  Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia‐induced activation of HIF‐1α , 2014, International journal of cancer.

[4]  Shan-shan Zhang,et al.  Chronic restraint stress decreases the repair potential from mesenchymal stem cells on liver injury by inhibiting TGF-β1 generation , 2014, Cell Death and Disease.

[5]  Ying-ying Jing,et al.  Autophagy prevents irradiation injury and maintains stemness through decreasing ROS generation in mesenchymal stem cells , 2013, Cell Death and Disease.

[6]  Yinghao Sun,et al.  Platelet‐derived growth factor‐BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells , 2013, Journal of cellular biochemistry.

[7]  Lin Zhu,et al.  Knockdown of NF-E2-related factor 2 inhibits the proliferation and growth of U251MG human glioma cells in a mouse xenograft model. , 2013, Oncology reports.

[8]  Y. Rui,et al.  Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors , 2013, Stem Cell Research & Therapy.

[9]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[10]  Ming-Chieh Lin,et al.  Lysophosphatidic acid receptor 2/3‐mediated IL‐8‐dependent angiogenesis in cervical cancer cells , 2012, International journal of cancer.

[11]  A. Karnoub,et al.  Mesenchymal stem cells in tumor development , 2012, Cell adhesion & migration.

[12]  T. Shibata,et al.  NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. , 2011, Neoplasia.

[13]  F. Schröder,et al.  The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. , 2011, European urology.

[14]  Lu Gao,et al.  Effects of Inflammatory Factors on Mesenchymal Stem Cells and Their Role in the Promotion of Tumor Angiogenesis in Colon Cancer* , 2011, The Journal of Biological Chemistry.

[15]  M. Kwak,et al.  NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. , 2011, Cancer research.

[16]  Lirong Song,et al.  Activation of Nrf2 by microcystin-LR provides advantages for liver cancer cell growth. , 2010, Chemical research in toxicology.

[17]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[18]  C. Drake.  Prostate cancer as a model for tumour immunotherapy , 2010, Nature Reviews Immunology.

[19]  W. Isaacs,et al.  Monocyte chemotactic protein‐1 (MCP‐1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia , 2010, The Prostate.

[20]  Yi Zhang,et al.  A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone , 2010, Nature Protocols.

[21]  L. Poellinger,et al.  HIF-1 induction attenuates Nrf2-dependent IL-8 expression in human endothelial cells. , 2009, Antioxidants & redox signaling.

[22]  N. Kikuchi,et al.  Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer , 2009, Clinical Cancer Research.

[23]  Yufang Shi,et al.  C/EBPβ Mediates Synergistic Upregulation of Gene Expression by Interferon‐γ and Tumor Necrosis Factor‐α in Bone Marrow‐Derived Mesenchymal Stem Cells , 2009, Stem cells.

[24]  Sushovan Guha,et al.  CXCL8/IL‐8 and CXCL12/SDF‐1α co‐operatively promote invasiveness and angiogenesis in pancreatic cancer , 2009 .

[25]  G. Lorusso,et al.  The tumor microenvironment and its contribution to tumor evolution toward metastasis , 2008, Histochemistry and Cell Biology.

[26]  T. Whiteside.  The tumor microenvironment and its role in promoting tumor growth , 2008, Oncogene.

[27]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[28]  F. Barry,et al.  IFN-γ and TNF-α differentially regulate immunomodulation by murine mesenchymal stem cells , 2007 .

[29]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[30]  P. Szlosarek,et al.  Tumour necrosis factor-α as a tumour promoter , 2006 .

[31]  D. Peehl,et al.  Expression of CCL5 (RANTES) and CCR5 in prostate cancer , 2006, The Prostate.

[32]  B. Sheu,et al.  Current concepts of tumor-infiltrating lymphocytes in human malignancies. , 2005, Journal of reproductive immunology.

[33]  L. Pfeffer,et al.  Interferon Induces NF-κB-inducing Kinase/Tumor Necrosis Factor Receptor-associated Factor-dependent NF-κB Activation to Promote Cell Survival* , 2005, Journal of Biological Chemistry.

[34]  P. Schumacker,et al.  Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. , 2005, Cell metabolism.

[35]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[36]  Jeremy J Mao,et al.  Mesenchymal stem cells: isolation and therapeutics. , 2004, Stem cells and development.

[37]  C. Shelley,et al.  Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Aihua Li,et al.  Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. , 2001, Clinical Cancer Research.

[39]  Y. Seo,et al.  Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors. , 2000, The Biochemical journal.

[40]  C. Wollheim,et al.  Synergistic activation of NF‐κb and inducible isoform of nitric oxide synthase induction by interferon‐γ and tumor necrosis factor‐α in INS‐1 cells , 2000, Journal of cellular physiology.

[41]  D. Defouw,et al.  Mast cell activation accelerates the normal rate of angiogenesis in the chick chorioallantoic membrane. , 1996, Microvascular research.

[42]  D. Defouw,et al.  Mapping of the microcirculation in the chick chorioallantoic membrane during normal angiogenesis. , 1989, Microvascular research.

[43]  Wan-Wan Lin,et al.  Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis , 2009, Nature.

[44]  F. Barry,et al.  IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. , 2007, Immunology letters.

[45]  P. Szlosarek,et al.  Tumour necrosis factor-alpha as a tumour promoter. , 2006, European journal of cancer.

[46]  L. Pfeffer,et al.  Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival. , 2005, The Journal of biological chemistry.

[47]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[48]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.